Clinical Trials Browser

Phase 1/2 × INDUSTRY × pomalidomide × Clear all

NCT04973605 2026-04-16

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT06953960 2026-02-23

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Phase 1/2 Recruiting

Multiple Myeloma, Neoplasms

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT01592370 2025-10-22

An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Phase 1/2 Completed

320 enrolled 35 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT07150104 2025-09-02

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

Phase 1/2 Active not recruiting

Multiple Myeloma

NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Phase 1/2 Terminated

103 enrolled 21 charts

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Phase 1/2 Completed

Multiple Myeloma, Recurrence

NCT05205252 2023-08-15

ARIA

Phase 1/2 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms

NCT03439280 2023-02-24

A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

Phase 1/2 Completed

50 enrolled 26 charts

Multiple Myeloma, Recurrence

NCT01464034 2022-08-01

A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Terminated

Multiple Myeloma

NCT01421186 2021-11-16

A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Completed

91 enrolled 19 charts

Multiple Myeloma

NCT02265510 2020-04-17

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Phase 1/2 Terminated

83 enrolled 31 charts

Neoplasm Metastasis

NCT02548962 2019-11-21

Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Terminated

11 enrolled 12 charts

Multiple Myeloma

NCT00537511 2019-11-19

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Phase 1/2 Terminated

22 enrolled 13 charts

Carcinoma, Small Cell

NCT01522872 2016-06-02

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Phase 1/2 Unknown

Hypoxia, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00833833 2016-04-27

MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1/2 Completed

259 enrolled 31 charts

Multiple Myeloma

NCT01541332 2016-03-10

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma